Dec25 Appendix 4C Cash Flow Report
Filed with ASX · · 5 pages · English
Nexalis Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Nexalis Therapeutics
- IRX Overview Presentation - SRX-25 and Nexalis
- $12.6m Facility to Drive SRX-25 Development
- Prospectus - Non-Renounceable Rights Issue Offer
- Drug Development Pipeline Bolstered and Capital Raise
- Trading Halt
Later from Nexalis Therapeutics
- Dec25 Quarterly Activities Report
- Preliminary Final Report
- First eligible participant screened - phase 1 IRX-616a study
- First patient dosed in IRX-616a Phase 1 trial
- Significant Milestone - First Patient Screened IRX-211 Ph2
Follow Nexalis Therapeutics into a list and get an email when it puts out news.
Follow Nexalis Therapeutics